ProfileGDS5678 / 1451450_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 53% 53% 61% 61% 45% 58% 63% 56% 57% 55% 54% 43% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1696548
GSM967853U87-EV human glioblastoma xenograft - Control 23.2859453
GSM967854U87-EV human glioblastoma xenograft - Control 33.3092653
GSM967855U87-EV human glioblastoma xenograft - Control 43.62761
GSM967856U87-EV human glioblastoma xenograft - Control 53.6296361
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1354445
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5980258
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7502163
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.378256
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4229557
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3721855
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2870754
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9937443
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2970853